This paper is in the following e-collection/theme issue:

#xInfectiousDiseases (28) JMIR Theme Issue: COVID-19 Special Issue (2450) #xPublicandGlobalHealth (34)

Published on in Vol 2, No 3 (2021): Jul-Sep

Preprints (earlier versions) of this paper are available at https://www.medrxiv.org/content/10.1101/2021.04.09.21255219v1, first published .
Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

Authors of this article:

Mark Jarrett1 Author Orcid Image ;   Warren Licht1 Author Orcid Image ;   Kevin Bock1 Author Orcid Image ;   Zenobia Brown1 Author Orcid Image ;   Jamie Hirsch1 Author Orcid Image ;   Kevin Coppa2 Author Orcid Image ;   Rajdeep Brar1 Author Orcid Image ;   Stephen Bello2 Author Orcid Image ;   Ira Nash1 Author Orcid Image
Article Authors Cited by (4) Tweetations (4) Metrics

Journals

  1. Jarrett M, Licht W, Bock K, Brown Z, Hirsch J, Coppa K, Brar R, Bello S, Nash I. Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”. JMIRx Med 2021;2(3):e33496 View
  2. Aggarwal N, Beaty L, Bennett T, Carlson N, Mayer D, Molina K, Peers J, Russell S, Wynia M, Ginde A. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase. International Journal of Infectious Diseases 2023;128:310 View
  3. Vawter N, Godino J, Lewis S, Northrup A, Samaniego J, Poblete J, Guereca J, Sharp S, Matthews E, Crespo N, Lucatero P, Vidaurrazaga M, Ramers C. COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center. BMC Infectious Diseases 2023;23(1) View
  4. . Peer Review of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”. JMIRx Med 2021;2(3):e33499 View